Study of regulating effect of resveratoral on C-myc gene in human small cell lung cancer H446 cells

doi:10.3877/cma.j.issn.1674-6902.2020.02.005

Abstract

Abstract:

Objective

The aim of the present study was to evaluate the effects of resveratrol on C-myc gene expression in small-cell lung cancer (SCLC) cell.

Methods

The H446 cell line of human small-cell lung cancer was used as the object of this study. The expression levels of C-myc were measured by western blot analysis and Real-time PCR in H446 cells treated with various concentrations of Res for 24 h and treated with the same concentration Res at different times. Cisplatin was used as the intervention for effect verification.

Results

The measure results of Western blot and Real-time PCR show that resveratrol has regulating effect on the expression of C-myc in H446 cells of human small-cell lung cancer. Along with the extension of the action time and the increase of the concentration, the expression of c-myc further decreased. These effects have the characteristic of concentration-and time-dependence, the difference has statistically significant (P<0.05). In addition, combined treatment with NAC and Res is found to be a inhibiting effect compared with either monotherapy while cisplatin and Res is found to be markedly more effective compared with either monotherapy, the difference has statistically significant (P0.05). However, the result of Western blot shows that the expression of C-myc in the cytonuclear protein has no significant difference in the combination group and the resveratrol group (P>0.05).

Conclusion

The present study demonstrated that resveratrol has a significant effect on C-myc expression in H446 cells. These findings suggest that the inhibiting effect of resveratrol on small cell lung cancer may be related to myc gene.

Key words: Resveratrol, H446 cells, Small cell lung cancer, Myc gene

Wangping Li, Lijie Ma, Lei Pan, Faguang Jin. Study of regulating effect of resveratoral on C-myc gene in human small cell lung cancer H446 cells[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 148-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.02.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I02/148

Figures/Tables 5

References 31

1	Hsieh TC, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule[J]. Biofactors, 2010, 36: 360-369.
2	Schnekenburger M, Dicato M, Diederich M. Plant-derived epigenetic modulators for cancer treatment and prevention[J]. Biotechnol Adv, 2014, 32: 1123-1132.
3	Chan S, Kantham S, Rao VM, et al. Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer's disease[J]. Food Chem, 2016, 199: 185-194.
4	Blanquer-Rosselló MD, Hernández-López R, Roca P, et al. Resveratrol induces mitochondrial respiration and apoptosis in SW620 colon cancer cells[J]. Biochim Biophys Acta, 2017, 861: 431-440.
5	Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives[J]. Cancer Lett, 2008, 269: 243-261.
6	Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms[J]. Arch Biochem Biophys, 2009, 486: 95-102.
7	Goswami SK, Das DK. Resveratrol and chemoprevention[J]. Cancer Lett, 2009, 284: 1-6.
8	Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1): 22-35.
9	Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010, 463(7283): 899-905.
10	Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment[J]. Signal Transduct Target Ther, 2018, 3(1): 5.
11	Wangping Li, Yun Shi, Ruixuan Wang, et al. Resveratrol promotes the sensitivity of small cell lung cancer H446 cell lines to cisplatin via mitochondrial apoptotic pathway[J]. Int J Oncol, 2018, 53: 2123-2130.
12	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
13	Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine[J]. Pers Med, 2014, 11(3): 309-321.
14	Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes[J]. Science, 1997, 275(5297): 218-220.
15	Llijie Ma, wangping Li, ruixuan Wang, et al. Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis[J]. Int J Oncol, 2015, 47(4): 1460-1468.
16	Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1): 22-35.
17	Meyer N, Penn LZ. Reflecting on 25 years with MYC[J]. Nat Rev Cancer, 2008, 8(12): 976-990.
18	Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins[J]. Nat Rev Mol Cell Biol, 2005, 6(8): 635-645.
19	George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer[J]. Nature, 2015, 524(7563): 47-53.
20	Semenova EA, Nagel R, Berns A, et al. Origins, genetic landscape，and emerging therapies of small cell lung cancer[J]. Genes Dev, 2015, 29(14): 1447-1462.
21	Helfrich BA, Kim J, Gao DX, et al. Barasertib(AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo[J]. Mol Cancer Ther, 2016, 15(10): 2314-2322.
22	Malynn BA, de Alboran IM, O′Hagan RC, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation[J]. Genes Dev, 2000, 14(11): 1390-1399.
23	Di Giacomo S, Sollazzo M, Paglia S, et al. MYC, cell competition，and cell death in cancer[J]. Genes, 2017, 8(4): 668-679.
24	Lu Q, Hong W. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells[J]. Cell Signal, 2009, 21(7): 1054-1059.
25	Noujaim D, van Golen CM, van Golen KL, et al. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells[J]. Oncogene, 2002, 21(29): 4549-4557.
26	李王平，马李杰，潘　蕾，等. 白藜芦醇诱导小细胞肺癌H446细胞凋亡机制的研究[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(1): 15-23.
27	van Golen CM, Soules ME, Grauman AR, et al. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells[J]. Oncogene, 2003, 22(17): 2664-2673.
28	van Golen CM, Castle VP, Feldman EL. IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma[J]. Cell Death Differ, 2000, 7(7): 654-665.
29	Lee MW, Kim DS, Kim HR, et al. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL[J]. Cell Prolif, 2019, 52(3): e12577.
30	Lu KV, Jong KA, Rajasekaran AK, et al. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line[J]. Lab Invest, 2004, 84(1): 8-20.
31	Grotzer MA, Castelletti D, Fiaschetti G, et al. Targeting Myc in pediatric malignancies of the central and peripheral nervous system[J]. Curr Cancer Drug Targets, 2009, 9(2): 176-188.

[1]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[2]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[3]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[4]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[5]	Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.
[6]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[7]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[8]	Suchi Han, Yanjing Huang. Correlation analysis between lactate dehydrogenase and risk of brain metastasis in small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 402-406.
[9]	Lili Bai, Yu Jiang, Liangliang Huang, Ying BAI, Min Zhang. Application of occupational therapy in postoperative rehabilitation of patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 411-415.
[10]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[11]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[12]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[13]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

Please choose a citation manager

Content to export